Molecular diagnostics firm BillionToOne said on Friday it was aiming at a valuation of up to $2.42 billion in its U.S. initial public offering.

BillionToOne has disclosed an expected size and price range for its initial public offering. The molecular diagnostics company said it will sell 3.8 million units at $49 to $55 apiece, according to a ...

(Reuters) -BillionToOne filed for an initial public offering in the United States on Tuesday. The company's filing comes at a time when U.S. IPO activity is picking up, reversing a slowdown from ...

Companion diagnostics can determine which patients are likely to benefit from a drug, but risks still remain. Companion diagnostics are bridging the gap between molecular diagnostics and therapeutics, ...

New techniques and materials are spurring the development of next-generation molecular diagnostics, critical for disease prevention and treatment. Here we present emerging technologies and tools in ...

SALT LAKE CITY, Sept. 17, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of ...

The Foundation for Innovative New Diagnostics (FIND), Molbio Diagnostics and the Indian Council of Medical Research (ICMR) announced today that the World Health Organization (WHO) has now endorsed ...

ChromaCode Co-Founders Alex Dickinson, Executive Chairman, Aditya Rajagopal, CTO, and CEO Greg Gosch talk about the formation of their molecular testing startup. Aditya: Interestingly, as an undergrad ...

The images were film-based, and subtle early signs of cancer could have been missed. Today, the same woman undergoes a ...

The goals and missions of the Division of Genomic Diagnostics & Bioinformatics (GDB) are to provide clinical, teaching and research expertise throughout the UAB academic medical center. The Division ...